# Axsome Therapeutics, Inc (AXSM) — Stock CV

Axsome Therapeutics, Inc is a $8.83B healthcare company. Revenue grew 56.9% over the last year, it currently loses money, and it holds more cash than debt.

> Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options.

## Identity

- **Ticker**: AXSM
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: NEW YORK, NY
- **Employees**: 925
- **Website**: https://www.axsome.com
- **Market cap**: $8.83B
- **Last price**: $168.52
- **Financial profile**: Solid

## Vitals (TTM)

- **Revenue**: $777M
- **Net income**: -$192M
- **Free cash flow**: -$72.0M
- **Net cash**: $205M
- **Revenue growth (YoY)**: 56.9%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 25 |
| Growth | 0 |
| Profitability | 0 |
| Health | 62 |
| Quality | 21 |
| Moat | 0 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [x] Revenue growing — +56.9% YoY
- [ ] Profitable — -$192M TTM
- [x] Profit growing — +36.2% YoY
- [ ] Generates cash — -$72.0M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $8.83B market cap
- [ ] Not printing shares — +22.4% shares over ~5y
- [ ] Proven track record — 0/10 profitable years
- [x] Financially stable — Altman Z 5.4 — safe

## Strengths

- High gross margin (93.2%)
- Revenue growing 56.9% year over year
- Net cash position after subtracting debt from cash
- Altman Z-Score 5.42 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 24.7% net margin
- Negative free cash flow (-$72.0M)
- Thin interest coverage (-27.0×)
- Loss-making in 10 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | — | -$130M | -$109M |
| FY2022 | $50.0M | -$187M | -$117M |
| FY2023 | $271M | -$239M | -$146M |
| FY2024 | $386M | -$287M | -$129M |
| FY2025 | $638M | -$183M | -$93.9M |

---

Source: https://stockcv.com/AXSM — derived from company filings; may be delayed or incomplete. Information, not investment advice.